Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): A Randomized Double-Blind Placebo-Controlled Multicenter Phase III Study to Evaluate the Safety and Efficacy of Anamorelin HCl in Patients With NSCLC-C

NCT01387269 is registered in ClinicalTrials.gov with Helsinn Therapeutics (U.S.), Inc as lead sponsor.

NCT NCT01387269
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01387269 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): A Randomized Double-Blind Placebo-Controlled Multicenter Phase III Study to Evaluate the Safety and Efficacy of Anamorelin HCl in Patients With NSCLC-C
Lead sponsor
Helsinn Therapeutics (U.S.), Inc
Phase
Phase 3
Overall status
Completed
Start date
July 31, 2011
Completion date
February 28, 2015
Enrollment
484 (actual)
Sites
60

Conditions

As the registry lists them; a condition with its own page is linked.

cachexia, non-small cell lung cancer